GlassScriptPhysician profile
Michael A Ohagan
NPI 1346579448
$3,686.63
in general payments reported to CMS, 2019-2025
28 companies · $796 in 2025
The $796 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $328 · 2022: $863 · 2023: $925 · 2024: $774 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,479 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,479.39 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $768.12 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $377.62 | 2022-2025 | |
| Lilly USA, LLC | $360.60 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $349.35 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $274.77 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $185.63 | 2022-2025 | Trintellix |
| Phathom Pharmaceuticals, INC. | $141.57 | 2024-2025 | Voquezna |
| Pfizer INC. | $130.02 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $112.60 | 2022-2023 | Belsomra, Steglatro, Verquvo |
| Biogen, INC. | $110.54 | 2024-2025 | Zurzuvae |
| Teva Pharmaceuticals USA, INC. | $104.09 | 2022-2025 | Ajovy |
| Edwards Lifesciences Corporation | $103.68 | 2021 | |
| Glaxosmithkline, LLC. | $103.61 | 2022-2024 | Trelegy Ellipta |
| Amgen INC. | $75.12 | 2022-2024 | Repatha, Otezla |
| Exact Sciences Corporation | $70.36 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $67.46 | 2022 | |
| Abbott Laboratories | $50.39 | 2022-2023 | Freestyle Libre 2 |
| Axsome Therapeutics, INC. | $48.31 | 2023-2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.41 | 2025 | Xifaxan |
| Astellas Pharma US INC | $44.47 | 2023-2024 | Veozah, Myrbetriq |
| Corium, LLC | $40.76 | 2023-2025 | Azstarys |
| Boston Scientific Corporation | $26.74 | 2025 | Watchman Flx |
| Inspire Medical Systems, INC. | $18.79 | 2025 | Inspire |
| Ibsa Pharma INC. | $16.60 | 2024 | Licart, Tirosint |
| Mylan Specialty L.P. | $16.00 | 2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.69 | 2023 | Spiriva Respimat, Stiolto Respimat |
| Impel Pharmaceuticals INC. | $14.56 | 2022 | |
| Bardy Diagnostics, INC. | $12.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ohagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.